ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1448

Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

Natalia Guajardo-Jauregui1, Iris Colunga2, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Cardiovascular, Disease Activity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is the leading cause of long-term mortality in SLE patients, and their increased risk of cardiovascular events is attributed to disease characteristics, such as the systemic inflammatory state associated with the disease. In this study we aimed to evaluate the association of disease characteristics, such as the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and anti-double stranded DNA antibodies (anti-dsDNA) titers, with echocardiographic parameters in patients with SLE.

Methods: This was a cross-sectional study. We recruited 75 SLE patients aged ≥ 18 years who fulfill the 2019 EULAR/ACR Classification Criteria for SLE. Patients with a previous cardiovascular event, another connective tissue disease or pregnancy were excluded. A transthoracic echocardiogram was performed by two certified echocardiographers blinded to clinical information. A blood sample was drawn to measure anti-dsDNA antibody titers and disease activity was evaluated with SLEDAI. Correlations were assessed with Spearman’s correlation coefficient (rs). A p-value < 0.05 was considered statistically significant.

Results: Median age of SLE patients was 37 (25-44) years with a median SLEDAI of 8.0 (4.0-12.0). The rest of demographic and clinical characteristics are shown in Table 1. We found a positive correlation between SLEDAI and left ventricular mass index (rs=0.243, p=0.036), between SLEDAI and the ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e’) (rs=0.277, p=0.016) and between SLEDAI and pulmonary arterial systolic pressure (PASP) (rs=0.271, p=0.019). We also found a positive correlation between anti-dsDNA and left ventricular mass index (rs=0.264, p=0.022), between anti-dsDNA and E/e’ (rs=0.295, p=0.010), and between anti-dsDNA and PASP (rs=0.292, p=0.011) (Figure 1).

Conclusion: Our study demonstrated significant associations between higher SLEDAI and anti-dsDNA with increased left ventricular mass index, E/e’ and PASP, which could lead to the progression of ventricular hypertrophy, diastolic dysfunction, and pulmonary hypertension respectively, suggesting a potential role of disease activity and anti-dsDNA in the development of adverse cardiac remodeling and function in SLE patients. A transthoracic echocardiogram may be helpful to detect early cardiovascular abnormalities, especially in patients with high disease activity and anti-dsDNA titers, and therefore, should be considered as part of the cardiovascular evaluation of SLE patients.

Supporting image 1

SLE systemic lupus erythematosus; T2DM type 2 diabetes mellitus; SLEDAI Systemic Lupus Erythematosus Disease Activity Index; dsDNA double stranded DNA; LV left ventricular; E/e’ the ratio between early mitral inflow velocity and mitral annular early diastolic velocity; LAVI left atrial volume index; LVEF LV ejection fraction; TAPSE tricuspid annular plane systolic excursion; PASP pulmonary arterial systolic pressure.

Supporting image 2


Disclosures: N. Guajardo-Jauregui: None; I. Colunga: None; J. Azpiri-López: None; D. Galarza-Delgado: None; J. Cardenas-De la Garza: None; R. Arvizu-Rivera: None.

To cite this abstract in AMA style:

Guajardo-Jauregui N, Colunga I, Azpiri-López J, Galarza-Delgado D, Cardenas-De la Garza J, Arvizu-Rivera R. Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/association-of-disease-activity-and-anti-double-stranded-dna-antibodies-titers-with-echocardiographic-parameters-in-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-disease-activity-and-anti-double-stranded-dna-antibodies-titers-with-echocardiographic-parameters-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology